In recent decades, as a result of improvement in prevention and treatment, the incidence of acute myocardial infarction (AMI) decreased by about one-third, while the incidence of heart failure (HF) did not follow that trend. [1] [2] [3] Guidelines provide clear therapeutic recommendations for both management of AMI and treatment of subsequent HF. Lifestyle changes and evidence-based medications, such as antiplatelets, statins, beta-blockers and angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) improve survival. [4] [5] [6] [7] [8] [9] In addition, if HF occurs, mineralocorticoid receptor antagonists (MRAs) and the implantable cardioverter-defibrillator (ICD) are indicated. 10 Therefore, the assessment of left ventricular ejection fraction (LVEF) after AMI is obligatory, since patients with HF require more intense treatment and careful follow-up strategy.
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The study of Gasior et al., 12 in the current issue of European Journal of Preventive Cardiology analysed combined data from the Polish registry of Acute Coronary Syndromes (PL-ACS) and national Acute Myocardial Infarction in Poland (AMI-PL), consisting of a total of 28,080 patients discharged after AMI (2009) (2010) (2011) (2012) (2013) , with LVEF 40%. The temporal trend in increase of patients age, number of co-morbidities, with fewer STEMI and cardiogenic shocks was demonstrated. Also, more percutaneous coronary interventions (PCIs) and fewer coronary artery by-pass graft (CABG) procedures were performed during index hospitalization. At discharge, a significant decrease in patients with low LVEF was revealed, while the percentage of guideline-recommended treatment (GRT) was high and stable. During follow-up, a temporal trend revealed higher frequency of PCIs, decrease in scheduled CABGs, and more ICDs and cardiac resynchronization therapy device (CRT) implantations. Most of the patients were treated by general practitioners, with the number of visits decreasing over time. At the 12-month follow-up, fewer recurrent AMIs were observed, but HF rehospitalizations and all-cause mortality did not decrease. After adjustment for sex and age, all-cause mortality and composite outcomes (death, myocardial infarction (MI), stroke or HF rehospitalization) revealed a significant decreasing trend.
This publication presents a comprehensive analysis of temporal trends of a large number of patients treated for AMI at the national level. However, in this type of analysis, several limitations can be recognised such as inferior level of evidence, coding inconsistencies, hidden confoundings and difficulties in verifying information. Also, the study provides only association, but not causation, and suffers from the biases of misclassification, intention-to-treat and adherence-over-time. In addition, information about LVEF before AMI, essential if the correct assessment of the contractility after AMI is required, is lacking.
It should be noted that AMI-PL is a national registry, while PL-ACS is an observational database that does not cover all of the hospitals in Poland. Since the study represents a single-country analysis, the results are not applicable for other countries, racial and ethnic groups. Furthermore, even in the same country, if an individual patient has treatment in several hospitals, the quality of diagnosis and management may be different, influencing the outcome.
It is difficult to compare results of publication by Gasior et al. with other publications covering a similar topic, since the periods of follow-up are in a different time-frame, ranging from mid-1990s to 2015. Therefore, the demographics, co-morbidities, availability of drugs, procedures and devices differ significantly. Also, the use of guideline-based physician education has risen, starting in the first decade of the 21st century which has improved cardiovascular patient survival. Two peaks in increase of evidence-based treatment have occurred, one between 1999-2000, and another one between 2007-2008. These peaks improved cardiovascular mortality and morbidity significantly, and coincide with guideline publications, [13] [14] [15] [16] [17] [18] Interestingly enough, a subsequent plateau was observed, with no further reduction in mortality. 19, 20 This plateau may be caused by the ageing of population, complex multivessel coronary anatomy and a high burden of co-morbidities. Also, although interventional treatment of AMI is widespread, due to the delay in PCI and incomplete revascularization, still many of patients are discharged with impaired LVEF. [21] [22] [23] [24] [25] [26] Furthermore, poor adherence and insufficient up-titration of medical therapy may also be an important contributing factor. The closest to the publication of Gasior et al. are the data from SWEDEHEART registry, 27 which also followed post-AMI patients with HF. This study demonstrated similar trends of increase in GRT, with a similar decrease in one-year mortality, at the end of followup (decrease to 14%). However, this registry analysed the period from 2005-2015, which makes comparison with the study of Gasior et al. difficult, because of different time-points and treatment options available.
It should be noted that in the study of Gasior et al., there is no information about the use of MRAs. Reports of the use of MRAs in treatment of HF after AMI are as low as 10% of patients. 28, 29 The major reasons are not only renal dysfunction, hyperkalaemia, but also because these drugs are introduced after all other drug target dosages are reached. 30, 31 Cardiac rehabilitation in medically stable outpatients with HF after AMI is guideline-supported. 30 Gasior et al. report the low use of this treatment modality, but data were acquired mostly before coronary revascularization became widely used. Adherence to GRT is not only geographically variable, but also reflects the various gaps in knowledge, accessibility and inequality of care. [32] [33] [34] Detecting the determinants of adherence to GRT in patients with HF after AMI is essential in order to identify parameters and groups related to poor or non-adherence. Due to the high incidence of post-AMI patients and the paucity of the healthcare system, many of the patients are followed by general practitioners (less than 49% had a cardiology control in the Gasior et al. study), with a mean number of visits decreasing over time. The lack of expertise and a proper indication for the next level of care may influence the long-term outcome adversely.
The improvement in evidence-based treatment can be reached at several levels, such as: up-skilling sessions focused on guidelines, quality improvement that promotes and embeds the guidelines in the healthcare process, and strengthening of doctor-patient relationships. It is up to every health system to use all/the most appropriate modalities to have the information they need. In the future, action is needed from European and national societies, health ministries and regulatory agencies to extract reliable and precise data. They should design and execute large, disease-specific, highquality, long-term European/national registries, and results can be analysed using appropriate statistical and analytical methods (e.g. nested case-control studies), 35 to overcome the above-mentioned biases. Cooperation and networking among European and national cardiovascular societies is mandatory to accelerate this process, increase the number of patients included, recognise geographic diversity and define disease-specific characteristics in particular countries. This information will help the understanding of specific cardiovascular conditions, empowering cardiologists for better diagnostic and treatment strategies.
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